Potentially reversible acute cerebellar toxicity associated with Minnelide

Sara Khanipour Roshan, Anthony D. Spano, Alexander M. McKinney, David R. Nascene

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Purpose: Minnelide is an experimental antineoplastic agent that is currently the subject of a phase 1 clinical trial for the treatment of pancreatic and gastrointestinal malignancies. In this study, we documented two cases of reversible acute cerebellar toxicity (REACT) associated with Minnelide and compared its radiological manifestations with other cerebellotoxic agents. Methods: Both patients had histories of progressive metastatic cancer and participated in a phase 1 clinical trial with Minnelide. They had an MRI examination including T2WI, FLAIR and SWI, axial and coronal DWI, and ADC map on admission and follow up. Results: In each patient, the initial MRI demonstrated increased signal on FLAIR and restricted diffusion in the cerebellar cortex without involvement of deep cerebellar nuclei or supratentorial areas. The presenting symptoms and the majority of imaging findings resolved on follow up MRI. Conclusion: To our knowledge, Minnelide has shown an uncommon radiologic pattern of isolated cerebellar cortical involvement compared to other causes of cerebellar toxicity. Since this is a new medication, physicians’ familiarity with the presenting symptoms and its temporal association with the imaging findings is important.

Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
Issue number4
StatePublished - Apr 1 2017


  • Cerebellar cortex
  • Cerebellar toxicity
  • Diffusion weighted imaging
  • Minnelide
  • Reversible acute cerebellar toxicity

PubMed: MeSH publication types

  • Case Reports
  • Journal Article


Dive into the research topics of 'Potentially reversible acute cerebellar toxicity associated with Minnelide'. Together they form a unique fingerprint.

Cite this